25/02/2010
ANA598 demostrates 73% cEVR in combination with interferon and ribavirin
No viral rebound observed during 12 weeks of ANA598 dosing; Positive safety data with AE profile comparable to control group.
Read the press release here.
Anadys Pharmaceuticals, Inc.
http://www.anadyspharma.com/
Share this page
DISCLAIMER
The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.
More...
